Compare MXCT & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | IGI |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 98.8M |
| IPO Year | 2021 | 2009 |
| Metric | MXCT | IGI |
|---|---|---|
| Price | $0.77 | $16.18 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 19.6K |
| Earning Date | 04-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,627,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $15.70 |
| 52 Week High | $3.49 | $17.09 |
| Indicator | MXCT | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 25.65 |
| Support Level | $0.75 | $15.78 |
| Resistance Level | $1.79 | $16.62 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 56.13 | 17.30 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.